Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 112

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 112
---
 and                                              |

| · | other risks and uncertainties, including those described in “Risk Factors” in this 
 prospectus.                                                                        |

Any forward-looking statements
that we make in this prospectus speak only as of the date of such statement, and we undertake no obligation to update such statements
to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events. Comparisons
of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless
expressed as such, and should only be viewed as historical data. You should, however, review the factors and risks we describe in the
reports we will file from time to time with the SEC after the date of this prospectus. See “Where You Can Find More Information.”

You should also read carefully
the factors described in “Risk Factors” in this prospectus, as well as elsewhere in this prospectus, to better understand
the risks and uncertainties inherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot
assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements
prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements,
you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and
plans in any specified timeframe, or at all.

| 56 |

<div align='center'>THE COMMITTED EQUITY FINANCING</div>

Overview

On January 17, 2025, we entered
into the Purchase Agreement with the Selling Shareholder. Sales of our Depositary Shares to the Selling Shareholder under the Purchase
Agreement, and the timing of any sales, will be determined by us from time to time in our sole discretion and will depend on a variety
of factors, including, among other things, market conditions, the trading price of our Depositary Shares and determinations by us regarding
the use of proceeds from any sale of such Depositary Shares. The net proceeds from any sales under the Committed Equity Financing will
depend on the frequency with, and prices at, which the Depositary Shares are sold to the Selling Shareholder. To the extent we sell shares
under the Purchase Agreement, we currently plan to use the net proceeds to fund our development programs, for working capital and other
general corporate purposes. We cannot